Benzinga | Nov 9, 2020 07:20AM EST

Recro Pharma Q3 EPS $(0.09) Beats $(0.20) Estimate, Sales $19.29M Beat $16.33M Estimate

Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.20) by 55 percent. This is a 52.63 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $19.29 million which beat the analyst consensus estimate of $16.33 million by 18.11 percent. This is a 23.63 percent decrease over sales of $25.25 million the same period last year.